Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinoxacin SCHEMBL29471771 | 0.90 | KDM4E (1.00) | ALDH1A1KDM4ETSHRLMNABLM | |
| SCHEMBL11153077 | 0.90 | ALDH1A1 (0.81) | ALDH1A1KDM4ETSHRLMNABLM | |
| Cinoxacin SCHEMBL43770 | 0.90 | KDM4E (1.00) | ALDH1A1KDM4ETSHRLMNABLM | |
| Cinoxacin SCHEMBL28034323 | 0.89 | KDM4E (0.97) | ALDH1A1KDM4ETSHRLMNABLM | |
| Cinoxacin SCHEMBL28034322 | 0.89 | KDM4E (0.97) | ALDH1A1KDM4ETSHRLMNABLM | |
| SCHEMBL11149089 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ETSHRLMNABLM | |
| SCHEMBL11149177 | 0.83 | ALDH1A1 (0.75) | ALDH1A1KDM4ETSHRLMNABLM | |
| SCHEMBL11149202 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KDM4ETSHRLMNABLM | |
| SCHEMBL11009750 | 0.81 | KDM4E (0.67) | ALDH1A1KDM4ETSHRLMNABLM | |
| SCHEMBL9040334 | 0.80 | KDM4E (0.67) | ALDH1A1KDM4ETSHRLMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20150044169-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | UNIV LELAND STANFORD JUNIOR (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044169-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 757/4885KDM4E 3386/4885TSHR 4850/4885 |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | ALDH1A1 3097/4885KDM4E 4855/4885TSHR 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.